


WHAT IS CLAIMED IS:

1. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:



I

wherein:

R¹, R², R⁴, and R⁵ are independently selected from the group consisting of H, halide, amino, unsubstituted -(C₁₋₃ haloalkyl), and unsubstituted -(C₁₋₃ alkyl);

R³ is a 5-membered heteroaryl optionally substituted with 1-4 R⁴⁵;

R⁶ is selected from the group consisting of -phenyl substituted with 1-5 R³⁶, -(C₁₋₃ alkylene)_ppyridinyl optionally substituted with 1-6 R³⁷, and a 6-10 membered heteroaryl optionally substituted with 1-6 R³⁷; wherein the carbonyl of Formula I is attached to an aromatic ring of the heteroaryl; wherein -(C₁₋₃ alkylene) is optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R³⁶ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -XR⁴², -C(=O)N(R⁴⁷)₂, -(C₁₋₄ alkylene)_pN(R⁵⁰)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R⁴³, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R³⁷ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -XR⁴², -C(=O)N(R⁴⁷)₂, -(C₁₋₄ alkylene)_pN(R⁵⁰)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R⁴³, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R³⁸ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), -CN, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R³⁹ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), -CN, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R^{40} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-\text{CN}$, and $-(C_{1-4} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^{44} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^{41} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, and $-\text{CN}$;

each R^{42} is independently selected from the group consisting of H, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})N(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p\text{aryl}$ optionally substituted with 1-10 R^{46} , $-(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-12 R^{43} , and $-(C_{1-4} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^{44} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^{43} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-\text{CN}$, $-\text{OH}$, $-\text{C}(=\text{O})R^{51}$, $-\text{N}(R^{50})_2$, and $-(C_{1-4} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^{44} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^{44} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, and $-\text{CN}$;

each R^{45} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_pN(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p\text{OR}^{49}$, $-\text{C}(=\text{O})N(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{38} , and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{39} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

alternatively, two adjacent R^{45} taken together form a ring which is selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{40} and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{41} ;

each R^{46} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, and $-\text{CN}$;

each R^{47} is independently selected from the group consisting of H, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, and unsubstituted $-(C_{1-5} \text{ haloalkyl})$;

each R^{48} is independently selected from the group consisting of H, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, and unsubstituted $-(C_{1-5} \text{ haloalkyl})$;

each R^{49} is independently selected from the group consisting of H, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, and unsubstituted $-(C_{1-5} \text{ haloalkyl})$;

each R^{50} is independently selected from the group consisting of H, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, and $-(C_{1-4} \text{ alkylene})N(R^{48})_2$; wherein $-(C_{1-4} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;


each R^{51} is a heteroaryl optionally substituted with 1-6 R^{52} ;

each R^{52} is a $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{46} ;

each X is selected from the group consisting of O, S, and NR^{48} ; and

each p is independently 0 or 1.

2. The compound of claim 1, wherein R^1 , R^2 , R^4 , and R^5 are H.
3. The compound according to any of claims 1-2, wherein R^3 is a pyrazolyl optionally substituted with 1-4 R^{45} .
4. The compound according to any of claims 1-3, wherein R^3 is an unsubstituted pyrazolyl.
5. The compound according to any of claims 1-3, wherein R^3 is a pyrazolyl substituted with one $-(C_{1-3} \text{ alkyl})$.
6. The compound according to any of claims 1-2, wherein R^3 is an imidazolyl optionally substituted with 1-4 R^{45} .
7. The compound according to any of claims 1-2 and 6, wherein R^3 is a imidazolyl substituted with one $-(C_{1-3} \text{ alkyl})$.
8. The compound according to any of claims 1-2, wherein R^3 is a triazolyl optionally substituted with 1-4 R^{45} .
9. The compound according to any of claims 1-2 and 8, wherein R^3 is an unsubstituted triazolyl.
10. The compound according to any of claims 1-2 and 8, wherein R^3 is a triazolyl substituted with one $-(C_{1-3} \text{ alkyl})$.
11. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:




I

wherein:

R^1 , R^2 , R^4 , and R^5 are independently selected from the group consisting of H, halide, amino, unsubstituted $-(C_{1-3} \text{ haloalkyl})$, and unsubstituted $-(C_{1-3} \text{ alkyl})$;

R^3 is selected from the group consisting of:



wherein each of R^7 - R^{35} is, independently, a substituent as defined anywhere herein or a single bond connecting R^3 to the isoquinoline ring; wherein only one of R^7 - R^{10} (when present) is a bond, only one of R^{11} - R^{14} (when present) is a bond, only one of R^{15} - R^{17} (when present) is a bond, only one of R^{18} - R^{20} (when present) is a bond, only one of R^{21} - R^{23} (when present) is a bond, only one of R^{24} - R^{26} (when present) is a bond, only one of R^{27} - R^{29} (when present) is a bond, only one of R^{30} - R^{31} (when present) is a bond, only one of R^{32} - R^{33} (when present) is a bond, and only one of R^{34} - R^{35} (when present) is a bond; wherein any one of the nitrogen atoms attached to R^7 , R^{11} , R^{15} , R^{18} , or R^{21} can serve as the point of attachment of R^3 to the isoquinoline ring; wherein any one of the carbon atoms attached to R^8 , R^9 , R^{10} , R^{12} , R^{13} , R^{14} , R^{16} , R^{17} , R^{19} , R^{20} , R^{22} , R^{23} , R^{24} , R^{25} , R^{26} , R^{27} , R^{28} , R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} , or R^{35} can serve as the point of attachment of R^3 to the isoquinoline ring; as that:

when the nitrogen atom to which R^7 is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^7 is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^8 is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^8 is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^9 is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^9 is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{10} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{10} is a single bond connecting R^3 to the isoquinoline ring;

when the nitrogen atom to which R^{11} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{11} is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{12} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{12} is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{13} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{13} is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{30} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{30} is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{31} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{31} is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{32} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{32} is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{33} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{33} is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{34} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{34} is a single bond connecting R^3 to the isoquinoline ring;

when the carbon atom to which R^{35} is attached serves as the point of attachment of R^3 to the isoquinoline ring, then R^{35} is a single bond connecting R^3 to the isoquinoline ring;

R^6 is selected from the group consisting of --phenyl substituted with 1-5 R^{36} , $\text{--(C}_{1-3}\text{ alkylene)}_p\text{pyridinyl}$ optionally substituted with 1-6 R^{37} , and a 6-10 membered heteroaryl optionally substituted with 1-6 R^{37} ; wherein the carbonyl of Formula I is attached to an aromatic ring of the heteroaryl; wherein $\text{--(C}_{1-3}\text{ alkylene)}$ is optionally substituted with 1-5 halide and/or 1-5 unsubstituted $\text{--(C}_{1-3}\text{ alkyl)}$;

R^7 is selected from the group consisting of a single bond, H, unsubstituted $\text{--(C}_{1-9}\text{ alkyl)}$, unsubstituted $\text{--(C}_{2-9}\text{ alkenyl)}$, unsubstituted $\text{--(C}_{2-9}\text{ alkynyl)}$, unsubstituted $\text{--(C}_{1-9}\text{ haloalkyl)}$, $\text{--(C}_{1-4}\text{ alkylene)N(R}^{48})_2$, $\text{--(C}_{1-4}\text{ alkylene)OR}^{49}$, $\text{--C(=O)N(R}^{48})_2$, $\text{--(C}_{1-4}\text{ alkylene)}_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{38} , and --carbocyclyl optionally substituted with 1-12 R^{39} ; wherein $\text{--(C}_{1-4}\text{ alkylene)}$ is optionally substituted with 1-5 halide and/or 1-5 unsubstituted $\text{--(C}_{1-3}\text{ alkyl)}$;

R^8 , R^9 , and R^{10} are independently selected from the group consisting of a single bond, H, halide, unsubstituted $\text{--(C}_{1-9}\text{ alkyl)}$, unsubstituted $\text{--(C}_{2-9}\text{ alkenyl)}$, unsubstituted $\text{--(C}_{2-9}\text{ alkynyl)}$, unsubstituted $\text{--(C}_{1-9}\text{ haloalkyl)}$, $\text{--(C}_{1-4}\text{ alkylene)}_p\text{N(R}^{48})_2$, $\text{--(C}_{1-4}\text{ alkylene)}_p\text{OR}^{49}$, $\text{--C(=O)N(R}^{48})_2$, $\text{--(C}_{1-4}\text{ alkylene)}_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{38} , and --carbocyclyl optionally substituted with 1-12 R^{39} ; wherein each $\text{--(C}_{1-4}\text{ alkylene)}$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $\text{--(C}_{1-3}\text{ alkyl)}$;

alternatively, one of R^7 and R^8 , R^8 and R^9 , or R^9 and R^{10} are taken together to form a ring which is selected from the group consisting of --heterocyclyl optionally substituted with 1-10 R^{40} and --carbocyclyl optionally substituted with 1-12 R^{41} ;

R^{11} is selected from the group consisting of a single bond, H, unsubstituted $\text{--(C}_{1-9}\text{ alkyl)}$, unsubstituted $\text{--(C}_{2-9}\text{ alkenyl)}$, unsubstituted $\text{--(C}_{2-9}\text{ alkynyl)}$, unsubstituted $\text{--(C}_{1-9}\text{ haloalkyl)}$, $\text{--(C}_{1-4}\text{ alkylene)N(R}^{48})_2$, $\text{--(C}_{1-4}\text{ alkylene)OR}^{49}$, $\text{--C(=O)N(R}^{48})_2$, $\text{--(C}_{1-4}\text{ alkylene)}_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{38} , and --carbocyclyl optionally substituted with 1-12 R^{39} ; wherein $\text{--(C}_{1-4}\text{ alkylene)}$ is optionally substituted with 1-5 halide and/or 1-5 unsubstituted $\text{--(C}_{1-3}\text{ alkyl)}$;

R¹², R¹³, and R¹⁴ are independently selected from the group consisting of a single bond, H, halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)_pN(R⁴⁸)₂, -(C₁₋₄ alkylene)_pOR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

alternatively, one of R¹¹ and R¹², R¹² and R¹³, or R¹⁴ and R¹¹ are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R⁴⁰ and -carbocyclyl optionally substituted with 1-12 R⁴¹;

R¹⁵ is selected from the group consisting of a single bond, H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)N(R⁴⁸)₂, -(C₁₋₄ alkylene)OR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein -(C₁₋₄ alkylene) is optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

R¹⁶ and R¹⁷ are independently selected from the group consisting of a single bond, H, halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)_pN(R⁴⁸)₂, -(C₁₋₄ alkylene)_pOR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

alternatively, one of R¹⁵ and R¹⁶ or R¹⁶ and R¹⁷ are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R⁴⁰ and -carbocyclyl optionally substituted with 1-12 R⁴¹;

R¹⁸ is selected from the group consisting of a single bond, H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)N(R⁴⁸)₂, -(C₁₋₄ alkylene)OR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein -(C₁₋₄ alkylene) is optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

R¹⁹ and R²⁰ are independently selected from the group consisting of a single bond, H, halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)_pN(R⁴⁸)₂, -(C₁₋₄ alkylene)_pOR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

alternatively, one of R¹⁸ and R¹⁹ or R¹⁸ and R²⁰ are taken together to form a heterocyclyl optionally substituted with 1-10 R⁴⁰;

R²¹ is selected from the group consisting of a single bond, H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)N(R⁴⁸)₂, -(C₁₋₄ alkylene)OR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein -(C₁₋₄ alkylene) is optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

R²² and R²³ are independently selected from the group consisting of a single bond, H, halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)_pN(R⁴⁸)₂, -(C₁₋₄ alkylene)_pOR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

alternatively, R²² and R²³ are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R⁴⁰ and -carbocyclyl optionally substituted with 1-12 R⁴¹;

R²⁴, R²⁵, and R²⁶ are independently selected from the group consisting of a single bond, H, halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)_pN(R⁴⁸)₂, -(C₁₋₄ alkylene)_pOR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

alternatively, one of R²⁴ and R²⁵ or R²⁵ and R²⁶ are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R⁴⁰ and -carbocyclyl optionally substituted with 1-12 R⁴¹;

R²⁷, R²⁸, and R²⁹ are independently selected from the group consisting of a single bond, H, halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)_pN(R⁴⁸)₂, -(C₁₋₄ alkylene)_pOR⁴⁹, -C(=O)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁸, and -carbocyclyl optionally substituted with 1-12 R³⁹; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

alternatively, R²⁷ and R²⁸ are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R⁴⁰ and -carbocyclyl optionally substituted with 1-12 R⁴¹;

R^{30} and R^{31} are independently selected from the group consisting of a single bond, H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p N(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p OR^{49}$, $-C(=O)N(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p \text{heterocyclyl}$ optionally substituted with 1-10 R^{38} , and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{39} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

alternatively, R^{30} and R^{31} are taken together to form a ring which is selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{40} and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{41} ;

R^{32} and R^{33} are independently selected from the group consisting of a single bond, H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p N(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p OR^{49}$, $-C(=O)N(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p \text{heterocyclyl}$ optionally substituted with 1-10 R^{38} , and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{39} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

R^{34} and R^{35} are independently selected from the group consisting of a single bond, H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p N(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p OR^{49}$, $-C(=O)N(R^{48})_2$, $-(C_{1-4} \text{ alkylene})_p \text{heterocyclyl}$ optionally substituted with 1-10 R^{38} , and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{39} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

alternatively, R^{34} and R^{35} are taken together to form a ring which is selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{40} and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{41} ;

each R^{36} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-XR^{42}$, $-C(=O)N(R^{47})_2$, $-(C_{1-4} \text{ alkylene})_p N(R^{50})_2$, $-(C_{1-4} \text{ alkylene})_p \text{heterocyclyl}$ optionally substituted with 1-10 R^{43} , and $-(C_{1-4} \text{ alkylene})_p \text{carbocyclyl}$ optionally substituted with 1-12 R^{44} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^{37} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-XR^{42}$, $-C(=O)N(R^{47})_2$, $-(C_{1-4} \text{ alkylene})_p N(R^{50})_2$, $-(C_{1-4} \text{ alkylene})_p \text{heterocyclyl}$ optionally substituted with 1-10 R^{43} , and $-(C_{1-4} \text{ alkylene})_p \text{carbocyclyl}$ optionally substituted with 1-12 R^{44} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R³⁸ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), -CN, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R³⁹ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), -CN, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R⁴⁰ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), -CN, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R⁴¹ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), and -CN;

each R⁴² is independently selected from the group consisting of H, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), -(C₁₋₄ alkylene)N(R⁴⁸)₂, -(C₁₋₄ alkylene)_paryl optionally substituted with 1-10 R⁴⁶, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-12 R⁴³, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R⁴³ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), -CN, -OH, -C(=O)R⁵¹, -N(R⁵⁰)₂, and -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁴⁴; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-5 unsubstituted -(C₁₋₃ alkyl);

each R⁴⁴ is selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), and -CN;

each R⁴⁶ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), unsubstituted -(C₁₋₅ haloalkyl), and -CN;

each R⁴⁷ is independently selected from the group consisting of H, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), and unsubstituted -(C₁₋₅ haloalkyl);

each R⁴⁸ is independently selected from the group consisting of H, unsubstituted -(C₁₋₅ alkyl), unsubstituted -(C₂₋₅ alkenyl), unsubstituted -(C₂₋₅ alkynyl), and unsubstituted -(C₁₋₅ haloalkyl);

each R^{49} is independently selected from the group consisting of H, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, and unsubstituted $-(C_{1-5} \text{ haloalkyl})$;

each R^{50} is independently selected from the group consisting of H, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, and $-(C_{1-4} \text{ alkylene})N(R^{48})_2$; wherein $-(C_{1-4} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-5 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^{51} is a heteroaryl optionally substituted with 1-6 R^{52} ;

each R^{52} is a $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{46} ;


each X is selected from the group consisting of O, S, and NR^{48} ;

each Y is selected from the group consisting of O and S; and


each p is independently 0 or 1.

12. The compound of claim 11, wherein R^1 , R^2 , R^4 , and R^5 are H.


13. The compound according to any one of claims 11-12, wherein R^3 is selected from the group consisting of:



14. The compound according to any one of claims 11-13, wherein R^3 is selected from the group consisting of:



15. The compound according to any one of claims 11-14, wherein R^3 is selected from the group consisting of:



16. The compound according to any one of claims 1-15, wherein R⁶ is –aryl substituted with 1-5 R³⁶.

17. The compound according to any one of claims 1-16, wherein R⁶ is –phenyl substituted with 1-5 R³⁶.

18. The compound according to any one of claims 1-17, wherein R⁶ is –phenyl substituted with one R³⁶.

19. The compound according to any one of claims 1-18, wherein R³⁶ is selected from the group consisting of halide, –heterocyclyl optionally substituted with 1-2 R⁴³, –CH₂heterocyclyl optionally substituted with 1-2 R⁴³, –Oheterocyclyl optionally substituted with 1-2 R⁴³, –NHheterocyclyl optionally substituted with 1-2 R⁴³, –O(C₁₋₄ alkyl), and –O(C₁₋₄ haloalkyl).

20. The compound according to any one of claims 1-15, wherein R⁶ is a 6-membered heteroaryl optionally substituted with 1-6 R³⁷.

21. The compound according to any one of claims 1-15 and 20, wherein R⁶ is –pyridinyl optionally substituted with 1-6 R³⁷.


22. The compound according to any one of claims 1-15 and 20-21, wherein R⁶ is –pyridin-3-yl optionally substituted with one R³⁷.


23. The compound according to any one of claims 1-15 and 20-21, wherein R⁶ is –pyridin-4-yl optionally substituted with one R³⁷.


24. The compound according to any one of claims 1-15 and 20-23, wherein R³⁷ is selected from the group consisting of halide, –(C₁₋₃ alkyl), –heterocyclyl optionally substituted with 1-2 R⁴³, –CH₂heterocyclyl optionally substituted with 1-2 R⁴³, –Oheterocyclyl optionally substituted with 1-2 R⁴³, –NHheterocyclyl optionally substituted with 1-2 R⁴³, –O(C₁₋₄ alkyl), and –O(C₁₋₄ haloalkyl).


25. The compound according to any one of claims 1-24, wherein R⁴³ is selected from the group consisting of unsubstituted –(C₁₋₃ alkyl), unsubstituted –(C₁₋₃ haloalkyl), and –carbocyclyl optionally substituted with 1-12 R⁴⁴.

26. The compound of claim 1, wherein the compound of Formula I is selected from the group consisting of:













































































27. The compound of claim 1, wherein the compound of Formula I is selected from the group consisting of:




















































































































28. The compound of claim 1, wherein the compound of Formula **I** is selected from the group consisting of:


















30. The compound of claim 1, wherein the compound of Formula **I** is selected from the group consisting of:









31. The compound according to any of claims 1, 11, and 26, wherein the compound of Formula **I** is selected from the group consisting of:



32. The compound according to any of claims 1, 11, and 28, wherein the compound of Formula **I** is selected from the group consisting of:



33. The compound according to any of claims 1, 11, and 28, wherein the compound of Formula **I** is selected from the group consisting of:



34. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1-33, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

35. Use of a compound according to any one of claims 1-33, or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for treating a disorder or disease in a patient, wherein the patient is human and the disorder or disease is selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, a bone or cartilage disease, osteoarthritis, lung disease, and a fibrotic disorder.

36. The use according to claim 35, wherein the disorder or disease is cancer.

37. The use according to claim 35, wherein the disorder or disease is pulmonary fibrosis.

38. The use according to claim 35, wherein the disorder or disease is idiopathic pulmonary fibrosis (IPF).

39. The use according to claim 35, wherein the disorder or disease is lung disease.

40. The use according to claim 35, wherein the disorder or disease is degenerative disc disease.

41. The use according to claim 35, wherein the disorder or disease is a bone/osteoporotic fracture.

42. The use according to claim 35, wherein the disorder or disease is a bone or cartilage disease.

43. The use according to claim 35, wherein the disorder or disease is osteoarthritis.

44. The use according to any one of claims 35-36, wherein the cancer is selected from the group consisting of: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma, and ovarian cancer.

45. The use according to any one of claims 35-36, wherein the cancer is selected from the group consisting of: lung cancer - non-small cell, lung cancer - small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer - basal and squamous cell, skin cancer – melanoma, small intestine cancer, stomach cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer, and adrenal cortical cancer.

46. The use according to claim 35, wherein the disorder or disease is a fibrotic disorder, wherein the fibrotic disorder is selected from the group consisting of: skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; adhesions; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis;

fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease, and radiation fibrosis.

- 47.** The use according to claim 44, wherein the disorder or disease is pancreatic cancer .